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http://dx.doi.org/10.1016/j.neuron.2012.12.008Research during the past decade has seen significant progress in the understanding of the genetic architec-
ture of autism spectrum disorders (ASDs), with gene discovery accelerating as the characterization of
genomic variation has become increasingly comprehensive. At the same time, this research has highlighted
ongoing challenges. Here we address the enormous impact of high-throughput sequencing (HTS) on ASD
gene discovery, outline a consensus view for leveraging this technology, and describe a large multisite
collaboration developed to accomplish these goals. Similar approaches could prove effective for severe
neurodevelopmental disorders more broadly.Introduction
The past decade has seen tremendous
advances in the genetics of autism spec-
trum disorders (ASDs). Rapidly evolving
genomic technologies combined with
the availability of increasingly large study
cohorts has led to a series of highly
reproducible findings (Betancur, 2011;
Devlin et al., 2011; Devlin and Scherer,
2012), highlighting the contribution of
rare variation in both DNA sequence
and chromosomal structure, placing
limits on the risk conferred by individ-
ual, common genetic polymorphisms,
underscoring the role of de novo germ-
line mutation, suggesting a staggering
degree of genetic heterogeneity, demon-
strating the highly pleiotropic effects of
ASD-associated mutations, and identi-
fying, definitively, an increasing number
of specific genes and chromosomal
intervals conferring risk. This progress
marks a long-awaited emergence of the
field from a period of tremendous uncer-
tainty regarding viable approaches to
gene discovery. At the same time, the
findings underscore the scale of the chal-
lenges ahead.1052 Neuron 76, December 20, 2012 ª2012Genetics of ASD before High-
Throughput Sequencing
Twin studies have consistently identified
a significant genetic component of ASD
risk (Hallmayer et al., 2011; Ronald and
Hoekstra, 2011) and gene discovery
dates back over a decade (Betancur,
2011; Devlin and Scherer, 2012). Recent
analyses demonstrate that common poly-
morphisms carry substantial risk for ASD
(Anney et al., 2012; Klei et al., 2012).
However, common polymorphisms have
so far proven difficult to identify and repli-
cate, probably because the relative risk
conferred by these loci is small and cohort
sizes have not yet reached those found
necessary to identify common polymor-
phisms contributing to other complex
psychiatric disorders (Devlin et al.,
2011). In contrast, a focus on rare and
de novo mutation has already been highly
productive in uncovering an appreciable
fraction of population risk and identifying
variation conferring relatively larger bio-
logical effects.
An example of the considerable traction
provided by a focus on rare inherited and
de novo variation can be found in theElsevier Inc.earliest successes in ASD genetics.
The protein products of risk genes for
patients ascertained with nonsyndromic
ASD, including NLGN4X, NRXN1, and
SHANK3, colocalize at the postsynaptic
density in excitatory glutamatergic syn-
apses with those coded for by genes first
identified in syndromic subjects, including
FMRP, PTEN, TSC1, and TSC2 (note,
however, that as gene identification
continues, ‘‘syndromic’’ genes are being
identified in nonsyndromic cases and
vice versa). These results are cause for
optimism with regard to the prospects
for identifying treatments that will have
efficacy well beyond the boundaries sug-
gested by mutation-defined subgroups.
Moreover, the themes highlighted in these
studies presaged the current era of gene
discovery, not only with regard to the
contribution of rare alleles and sporadic
germline mutations, but also by providing
the first concrete evidence of the tremen-
dous pleiotropy and variable penetrance
that are now considered characteristic of
ASD risk loci.
Analyses of chromosome microarrays
have provided compelling evidence that
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NeuroViewsubmicroscopic variations in chromo-
somal structure, called copy number
variation (CNV), contribute to ASD risk
(Betancur, 2011; Cooper et al., 2011;
Pinto et al., 2010; Sanders et al., 2011).
Certain CNVs are recurrent, often due to
either the presence of low-copy repeats
or subtelomeric deletions, and within
some of these, the attendant risk has
been related to a single gene (e.g.,
NRXN1 in 2p16.3, SHANK3 in 22q13.3
deletions, and MBD5 in 2q23.1) (Betan-
cur, 2011). With the widespread use of
microarrays in the clinical setting, accom-
panied by increasingly large-scale anal-
yses of research cohorts, the field is
beginning to consolidate population level
data for CNV with some clear findings:
(1) between 5%–10% of previously unex-
plained cases will carry an ASD-CNV; (2)
both de novo and transmitted CNV confer
risk; (3) rare CNV generally confers larger
risks than are typically associated with
common variants; however, many of
these high-risk regions appear to con-
tribute to ASD through a complex pattern
of inheritance; and (4) the majority of
confirmed ASD loci show both variable
expressivity and pleiotropic effects.
A recent analysis of structural variation
in ASD families from the Simons Simplex
Collection, focusing on comprehensively
assessed quartets of mother, father,
ASD proband, and unaffected sibling
(Sanders et al., 2011), serves as a useful
illustration. Large, rare de novo CNV
showed a 3-fold increase in probands
relative to their matched siblings, yielding
a highly significant difference. Moreover,
the de novo events in probands were
found to carry about ten more genes on
average even after accounting for CNV
size. Among the many results from these
data, one of special salience is that no
matter how inherited CNVs were parsed
for analysis, no significant difference
between probands and siblings emerged,
even though there were many more in-
herited than de novo CNVs. A plausible
interpretation of these results is that de
novo events that alter gene function
have a much higher signal-to-noise ratio
than inherited CNVs that also effect gene
function; put another way, gene-rich de
novo CNVs are highly likely to be
capturing one or more ASD genes, while
inherited gene-rich CNVs are less likely
on average to harbor ASD genes.With regard to pursuing biological
studies, a drawback of CNVs is their
tendency to encompass multiple genes.
Accordingly, if the genetic architecture
of sequence variation in ASD mirrored
that suggested by CNV, HTSwould repre-
sent an extremely important addition to
the genomic armamentarium.
The ASC, Sequencing, and Gene
Discovery in ASD
Against this backdrop, the Autism
Sequencing Consortium (ASC) was
formed in 2010, in anticipation of both
the tremendous impact HTS would have
on ASD genomics as well as the many
challenges the field would face as a
consequence. Now including more than
20 research groups, the ASC has as its
goal to collectively exploit sequencing
approaches to resolve a substantial frac-
tion of the genetic factors involved in
ASD. While there are probably many
hundreds of undiscovered ASD loci,
emerging data provide sufficient empirical
evidence upon which to develop sound
and systematic approaches to identifying
these loci.
From the outset, the effort to constitute
the group and define the objectives for the
ASC was faced with the challenge of
balancing the obvious benefits of working
cooperatively with the strongly held
conviction that a diversity of approaches
and the presence of multiple competing
efforts has played, and will continue to
play, an indispensable role in the field’s
rapid progress. The participating investi-
gators undertook an effort to address
the range of related issues, including
data sharing, prospectively and prior to
the widespread availability of HTS data.
In 2011, the ASC held an open meeting
of investigators, funders, and other stake-
holders to refine and crystallize the plans
and proposals. The meeting, which
included more than 100 onsite partici-
pants (see Table S1 available online) and
additional web participants, was orga-
nized around three working groups: (1)
sequence technology, data harmoniza-
tion, and statistical inference (B. Devlin
and M. Daly, Chairs); (2) samples and
phenotypes (J. Buxbaum and M. Gill,
Chairs); and (3) future directions (T. Leh-
ner andM. State, Chairs). Working groups
addressed a variety of issues including
study designs, statistical approaches,Neuron 76, Desample availability and composition,
data normalization, bioinformatics chal-
lenges, and the integration of gene dis-
covery into broader efforts at translational
neuroscience (Table S2). The meeting
was video cast and can be accessed
at http://videocast.nih.gov/pastevents.asp.
We present a synthesis and summary
of that meeting, reflecting both a current
view of the field and consensus recom-
mendations for gene discovery.
In light of the high degree of genetic
heterogeneity in ASD, it was apparent
that HTS would provide a powerful plat-
form for gene discovery. Whole-genome
sequencing (WGS) can detect structural
variation of all types, ranging from gross
chromosomal rearrangements to CNV
and insertion deletions (indels), while
also providing highly sensitive single-
base resolution. Similarly, whole-exome
sequencing (WES) can reliably detect
single-nucleotide variants (SNVs) in the
coding segments of the genome,many in-
dels, and some CNV. Of course, both
technologies provide the ability to identify
rare alleles to a degree that is not possible
on genotyping platforms.
To date, four large-scale ASD WES
studies have been carried out in trios,
namely a proband with ASD and the bio-
logical parents, or in quads, a trio plus
an unaffected sibling (Iossifov et al.,
2012; Neale et al., 2012; O’Roak et al.,
2012; Sanders et al., 2012). Among the
1,000 families assessed by the four
studies, the rate of de novo loss-of-func-
tion (LoF) variation was consistently found
to be significantly higher in cases com-
pared to controls, allowing for the devel-
opment of rigorous statistical approaches
to identifying specific risk genes. Indeed,
six ASD genes were identified, CHD8,
DYRK1A, GRIN2B, KATNAL2, POGZ,
and SCN2A, because they carried recur-
rent, highly damaging de novo events.
While SCN2A has been previously impli-
cated in epilepsy, none of these genes
were known to carry ASD risk. Another
key finding, one that will prove useful for
gene discovery, was that roughly half of
all de novo LoF mutations seen in ASD
probands fall in ASD genes, with about
12% of ASD subjects showing a de novo
LoF mutation.
TheseWESstudies foundabackground
rate of missense de novo variation that is
more than 10-fold higher than that forcember 20, 2012 ª2012 Elsevier Inc. 1053
Figure 1. Expected Yield of Identified ASD Risk Genes as a Function of the Number of Trios Evaluated for De Novo LoF Variants
Analyses (data not shown) have demonstrated that for 8,000 families, a threshold of three ormore de novo LoF variants (right) is sufficient to declare genome-wide
significance. Using two or more de novo LoF as a criteria (left) would identify80 likely ASD genes with an FDR of 0.1. As we learn more about annotation of truly
damagingmissense de novo variants, the rate of discovery will rise dramatically—and we anticipate that this will happen soon by our work and that of others such
as the 1,000 genomes project. In addition, other forms of discovery are not modeled but will lead to additional gene discovery. The analyses underlying this figure
are further described in Sanders et al. (2012).
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undoubtedly include risk alleles; however,
only a 5%–10% excess of suchmutations
was found in ASD cohorts, a difference
that did not reach significance collectively
across studies. Accordingly, it is not yet
possible to confidently assign risk to this
broad category of mutation, nor to estab-
lish an agreed upon threshold for the
significance of observing ‘‘recurrent’’ de
novo missense mutations in a given
gene. Given the relevance of LoF alleles,
this difficulty surely reflects the signal-to-
noise problems engendered by neutral
background variation and the difficulties
that attend differentiating the subset of
truly functional missense variations.
The interpretation of case-control
exome sequencing has also not been as
straightforward as family studies evalu-
ating de novo LoF events. For example,
WES of a sample of 1,000 cases and
1,000 controls and inspection of the six
novel ASD genes just described showed,
in hindsight, only a slight excess of LoF
mutations in KATNAL2 and CHD8 in
cases, a difference that did not approach
statistical significance (Neale et al., 2012).
Indeed, across the entire genome, no
genes were found to harbor a sufficiently
large excess of rare alleles in cases versus
controls to support a significant associa-
tion after accounting for multiple compar-
isons (Liu et al., personal communication).
These results are consistent with the1054 Neuron 76, December 20, 2012 ª2012multiple lines of evidence supporting
a large number of ASD risk genes scat-
tered throughout the genome. Methods
to extract signal from case-control
studies, alone and in combination with
de novo data, are rapidly evolving. Still,
it seems reasonable to conclude that
large studies, involving tens of thousands
of subjects, will be necessary to identify
risk loci using standard analyses of muta-
tion burden in case-control samples.
The ASC’s Proposed Path Forward
The path forward is either WES or WGS in
large cohorts. Because of its higher
signal-to-noise ratio, discovery of de
novo mutations, especially LoF mutations
that cluster in the same gene among unre-
lated individuals, is an immediately
productive approach to gene discovery
and will be emphasized. As the number
of trios or quads sequenced grows line-
arly, the rate of gene identification is pre-
dicted to accelerate (Figure 1). Based on
the first results from the ASC sites, the
value of expanding efforts in search of
recurrent de novo events is clear. If HTS
were to be performed on 8,000 families,
and even ignoring other sources of key
information, the experiment should yield
between 40–60 novel ASD genes and
a large number of additional genes falling
just short of significance that could readily
be confirmed via targeted sequencing in
additional large patient cohorts (Figure 1).Elsevier Inc.Efforts of this scale are underway.
To give some examples, the Simons
Foundation has committed to sequencing
more than 2,600 quartets, the ARRA
Autism Sequencing Consortium has
finished 400 families, Genome Canada is
supporting the sequencing of 1,000 trios
and families, and the UK10K project is tar-
geting 800 ASD cases in the 10,000 to
be sequenced. AutismSpeaks, in partner-
shipwith the BeijingGenomics Institute, is
committed to whole-genome sequencing
of 60 families and has proposed an ulti-
mate target of 2,000 families.
A key related question is whether an
even higher yield of ASD genes can be
gleaned simply by making more effective
use of data generated in ongoing experi-
ments. In fact, it is a near certainty that
there will be significant traction in evalu-
ating other types of mutations beyond
de novo LoF variants. Ongoing research
promises to refine the interpretation of
various classes of mutations, including in-
herited variation from family and case-
control analyses, for which the chief
obstacle is the high frequency of appar-
ently neutral rare variation in the genome.
In addition, there are already emerging
successes focusing on recessive and X-
linked LoF variation. These efforts may
be aided through the study of sequence
data in unusual high-risk extended pedi-
grees that are also available. Thus, based
on refined interpretation of sequence, we
Figure 2. A Pathway for Discovering Novel Risk Genes
for Autism Spectrum Disorders
Beyond the genes identified by de novo events, as illustrated in
Figure 1, inherited variation will also prove useful for identifying
risk genes, the simplest to interpret being variation acting
recessively. Potentially imbuing far greater discovery power
will be two other sources of data: genetic data of various kinds,
such as genomic regions already implicated in risk for ASD by
copy number variation, and metadata from other complemen-
tary fields, such as neuroscience and so called ‘‘omics’’ (e.g.,
pathways of functionally related genes). With these additional
sources of information, it will be possible to identify a substan-
tial fraction of ASD genes, providing sufficient grist for clinical
geneticists to predict risk and for pharmacologists to develop
therapeutics.
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genes. Progress in this area will
also require methods to combine
data on inherited variation with
data on de novo events.
The ASC recognizes that a focus
on DNA sequence, by itself, is insuf-
ficient. There are additional sources
of information that can be brought to
bear to identify novel ASD genes
(Figure 2). RNA-seq and Chip-seq
studies of typical and ASD brains
offer an increasingly accurate
picture of gene coexpression and
regulatory networks, thereby identi-
fying processes altered in ASD, both
by themselves and by overlap with
genes identified as disrupted in
ASD. And RNA-seq studies of peri-
pheral samples (blood or induced
neural cells) have the potential to
survey thousands of individuals to
identify ASD-related biological
signatures. Bearing in mind that
one out of every two de novo LoF
events found in probands hits an
ASD gene, these kinds of biological
information can be exploited to
separate the ASD ‘‘wheat from the
chaff.’’ Moreover, CNVs have
already identified many regions of
the genome as harboring one ormore ASD genes, so there will be ways
of combining CNV and sequence informa-
tion to identify additional ASD genes. If
other sources of information prove as
useful as we anticipate, the yield of
ASD genes could easily amplify well
beyond that predicted by Figure 1, paving
the way for systems biological and
neurobiological follow-up. In addition,
understanding gene-environment interac-
tion and gene-environment correlation
remains an important long-term goal in
ASD, and such approaches will be enor-
mously facilitated by this gene discovery.
Beyond gene discovery, integration of
information as depicted in Figure 2 holds
the promise for clarifying the etiology
and biology of ASD. Eventually we foresee
identifying ASD-related biological signa-
tures to define subgroups enriched for
disruptions in specific pathways and, ulti-
mately, to identify subsets of patients
amenable to specific treatments. For brain
and blood samples, it is also now possible
to interrogate epigenetic modifications,
mechanisms that are likely to play asubstantial role in ASD. Other potentially
uncharacterized risks include rare disrup-
tion in the mitochondrial genome and
alterations to the microbiome. The micro-
biome, thought to contribute as much as
10% of the metabolites in the blood-
stream, has recently been shown to affect
behavior in model systems. If it is a medi-
ator of ASD risk, it would be particularly
amenable to intervention.
The ASC Challenges Ahead
Collaboration
The empirical data to develop the ASC
strategy involved three ASC groups who
shared their data prior to publication
(Neale et al., 2012; O’Roak et al., 2012;
Sanders et al., 2012). This is a model
that we strongly favor in the ASC, as it
strikes a workable balance between pre-
serving intellectual diversity and competi-
tiveness while still reaping the benefits of
cooperative research.
Samples
Approximately 8,000–10,000 families are
available and poised for discovery effortsNeuron 76, Decembamong the groups contributing to
the ASC, and these all should be
sequenced with HTS approaches.
However, we believe the collection
of additional ASD cohorts remains
a vitally important priority that would
dramatically accelerate gene dis-
covery, validation and characteriza-
tion of mutation spectra in ASD-risk
genes, clarify genotype-phenotype
relationships, and provide a critical
substrate for ongoing effort to
identify shared neurobiological
mechanisms and treatment targets
among patients with diverse genetic
etiologies.
Bioinformatics
WES is currently favored over WGS
because of its lower-cost, lower-
informatics overhead and ease of
interpretation. However, WGS pro-
vides a more comprehensive view
of both sequence and structural
variation, does not require target
capture, and is able to better interro-
gate regions of high GC content that
may be particularly prone to de novo
mutation. The transition from WES
to WGS over the next several
years is likely, given the trajectory
of costs and the steady introduction
of new sequencing technologies.These developments will undoubtedly
contribute further to the understanding
of ASD but, in our view, should not
delay current WES efforts, which are
already driving new studies of the biology
of ASD.
Sequencing and analyzing data from
tens of thousands of samples generates
a volume of data that overwhelms stan-
dard approaches to data storage and
backup. Movement of data is cumber-
some, time consuming, or infeasible.
Because fair collaboration among ASC
researchers requires that all participants
have equal access to all data and equal
opportunity to analyze it, and because
variant detection remains a work in prog-
ress, the ASC solution is to create a bio-
informatics infrastructure to collate data
at a single site for analysis. A strength of
this approach is that it has capacity for
massive data sharing and joint analyses,
thereby accelerating progress while
avoiding the pitfalls of beginning data
harmonization post hoc once individual
studies have been completed ander 20, 2012 ª2012 Elsevier Inc. 1055
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nizes the prerogative of individual groups
to investigate their own data freely.
Foundational Resources for
Functional and Systems Biological
Analyses
As novel genes and pathways are identi-
fied, functional analyses will take these
findings forward to understand mecha-
nisms of pathophysiology. While elegant
functional approaches exist, high-
throughput methods will be essential.
This need is even more acute when one
considers that many variants of unknown
significance will be identified, so that aug-
menting genetic findings with in vitro
assays could help determine whether
a particular gene plays a bona fide role
in ASD.
Integration with Other Psychiatric
Disorders
ASC data will be further enhanced by
HTS efforts focused on disorders that
are already showing overlapping risk
loci, including intellectual disability, epi-
lepsy, and schizophrenia. It is reason-
able to predict that knowledge about all
these disorders will be enhanced by
collaboration and open sharing of data
and results.1056 Neuron 76, December 20, 2012 ª2012SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables
and a full list of The Autism Sequencing Consor-
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